Role of Mitochondrial Bioenergetics in Resilience for Gynecologic Cancer
ConditionGynecologycal Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age50+
SponsorWake Forest University Health Sciences
About this trial
The purpose of this research study is to see if patients with endometrial and ovarian cancer are willing to complete physical and cognitive assessments before treatment and again after treatment has ended.
Eligibility criteria
Qualifiers
Ability to understand and willingness to sign an IRB-approved informed consent
Age ≥50 years at the time of enrollment
Newly diagnosed or suspected FIGO Stage II-IV ovarian/primary peritoneal/fallopian tube carcinoma of any histological subtype OR FIGO Stage II-IV endometrial carcinoma of any histological subtype
Planned, standard of care treatment consisting of neoadjuvant chemotherapy, tumor reduction surgery, and adjuvant chemotherapy OR tumor reduction surgery with adjuvant chemotherapy
Disqualifiers
Previously treated for ovarian or endometrial cancer
History of brain metastases, whole brain irradiation, poorly controlled psychiatric disorders defined by hospitalization within the last 3 months for psychiatric diagnoses, traumatic brain injury, cerebrovascular event, or dementia
Currently taking anti-amyloid agents, cholinesterase inhibitors, or glutamate regulator
Documented physical or psychological comorbidity that would limit participant's ability to understand or comply with study procedures for the entire length of the study
Trial design
Treatments tested in this trial
- muscle sample
- blood draw
Treatment groups
30 Participants
are divided into 1 treatment groupSponsors and collaborators
Wake Forest University Health Sciences
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov